Synexa Life Sciences expands operations in North America with new Rockville laboratory site
World Leaders in Biomarker and Bioanalysis Research Services
We are deeply saddened to share the news with you that our friend, colleague, mentor and Chief Scientific Officer, Matti Kimberg, unexpectedly passed away on 10 July 2022. Matti was not only a truly extraordinary scientist but more importantly also a remarkable person whose gentle nature, enthusiasm and sincere concern for people left an indelible mark on all that he met. Matti was instrumental in helping to weave the fabric of Synexa’s ethos and identity and he will be greatly missed.
Our hearts go out to Matti’s family and loved ones for whom this is as much a shock as it is to his Synexa Family. Your patience and support will be greatly appreciated over this period. Dr. Justin Devine (Synexa’s CMO) will in the interim take on the role of Chief Scientific Officer.
Biomarker & Bioanalytical expertise
Synexa Life Sciences has been providing expert insights for the clinical development of therapeutics for almost 20 years.
Insights that will improve the quality of decision-making through each stage of a therapeutic’s development.
Invaluable insight into the bioanalytical profile of large molecule therapeutics.
Our human in vitro translational ProtoTrials® platform provides unique and translatable insights into a therapeutic’s potential, safety and efficacy.
Services &
Capabilities
- Cell and gene therapy bioanalysis
- Large and novel molecule bioanalysis
- Vaccines
- Biosimilars
- Functional and translational assays
- Biomarker discovery, detection and interpretation
